Doer Bio Named to '2023 Top 100 Innovative Breakthrough Enterprises' Ahead of IPO Filing
Doer Biologics
Biological Drug Developer
March 14-16, 2024, BIOCHINA2024 was held at the Suzhou International Expo Center. Doer Biologics was honored to be featured."Top 100 Innovative Breakthrough Enterprises in 2023"。
DOER
BIOCHINA2024 Conference Covers Frontiers Such as Antibody Drugs, Cell Therapy, Gene Therapy, Nucleic Acid Drugs, Small Molecule Innovative Drugs, and Synthetic Biology, Building a Multi-Ecosystem Involving Government, Clinics, Enterprises, Research, and Capital. Dr. Yanshan Huang, Founder/CEO of Zhejiang Doer Biologics Co., Ltd., Was Invited to Participate in the Roundtable Discussion.“Market Space of Peptide Drug Industry from the Perspective of GLP-1 Transaction CooperationRelated ContentExpressed their own views and opinions.
Dr. Huang Yanshan
About Doer Biologics
Doer Biologics is a research and development enterprise specializing in the development of innovative biopharmaceuticals, owning independent intellectual property rights technology platforms. The company focuses on the development of innovative biopharmaceuticals in the fields of metabolic diseases and cancer. Doer Biologics concentrates on developing next-generation biologics such as multi-specific innovative proteins and antibody drugs based on multi-domain structures to provide better therapeutic solutions for unmet clinical needs in endocrinology, oncology, and other fields. Adhering to the rigorous "DOER" scientific spirit, and with the corporate vision of contributing to human health through diligent and innovative work, Doer Biologics will continue to focus on the development of innovative biopharmaceuticals.